We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion (BRVO)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2010 by Shahid Beheshti University of Medical Sciences.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01044329
First Posted: January 7, 2010
Last Update Posted: January 7, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Labbafinejad Medical Center
Information provided by:
Shahid Beheshti University of Medical Sciences
January 6, 2010
January 7, 2010
January 7, 2010
January 2010
August 2010   (Final data collection date for primary outcome measure)
Visual acuity [ Time Frame: 6 months ]
Same as current
No Changes Posted
central macular thickness [ Time Frame: 6 months ]
Same as current
Not Provided
Not Provided
 
Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion
Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion
This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Branch Retinal Vein Occlusion
  • Drug: Bevacizumab
    Intravitreal, 1.25 mg, 3 times, one month apart.
  • Drug: Triamcinolone Acetonide
    Intravitreal, 2 mg, 2 times, two months apart.
  • Active Comparator: Intravitreal bevacizumab
    Intervention: Drug: Bevacizumab
  • Active Comparator: Intravitreal triamcinolone
    Intervention: Drug: Triamcinolone Acetonide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
90
December 2010
August 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Recent onset (less than 3 months) BRVO

Exclusion Criteria:

  • Any previous intervention
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
 
 
NCT01044329
8900
Yes
Not Provided
Not Provided
Alireza ramezani, Ophthamic research center
Shahid Beheshti University of Medical Sciences
Labbafinejad Medical Center
Not Provided
Shahid Beheshti University of Medical Sciences
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP